Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | MicrobiomeTrials

← Back to trials

NCT04862663

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2021-05-10Est. Completion: 2027-11-01

Enrollment target: 895 participants

Locations

Research Site, Tucson, Arizona, United States
Research Site, Fountain Valley, California, United States
Research Site, Glendale, California, United States
Research Site, Los Angeles, California, United States
Research Site, Los Angeles, California, United States
Research Site, Napa, California, United States
Research Site, Newport Beach, California, United States
Research Site, San Francisco, California, United States
Research Site, Santa Barbara, California, United States
Research Site, Santa Rosa, California, United States
Research Site, Aurora, Colorado, United States
Research Site, New Haven, Connecticut, United States
Research Site, Newark, Delaware, United States
Research Site, Quincy, Illinois, United States
Research Site, Fort Wayne, Indiana, United States
Research Site, Louisville, Kentucky, United States
Research Site, Louisville, Kentucky, United States
Research Site, Baton Rouge, Louisiana, United States

Other microbiome trials you might be interested in

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)Phase 2Recruiting

Breast Neoplasms

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate agains…

Hot Springs, United StatesEst. completion Mar 13, 2028

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerPhase 1Recruiting

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study …

Duarte, United StatesEst. completion May 30, 2029

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.